Peetz Christopher 4

What Happened
Christopher Peetz, CEO of Mirum Pharmaceuticals (MIRM), was awarded a total of 185,500 derivative equity awards on January 28, 2026 (three separate grants of 67,000; 43,500; and 75,000 units). Each award was reported at $0.00 per unit (restricted stock units and performance restricted stock units), meaning these are compensation awards that convert to common shares subject to vesting and/or performance conditions rather than open-market purchases or sales.

Key Details

• Transaction date: January 28, 2026; reported on Form 4 filed January 30, 2026 (timely within the usual two-business-day window).
• Price: $0.00 per unit (derivative awards — RSUs/PSUs).
• Total units awarded: 185,500 (67,000; 43,500; 75,000).
• Shares owned after transaction: Not provided in the excerpt of the filing.
• Footnote highlights:
  • F2: Each restricted stock unit converts to one share of common stock upon vesting.
  • F1: One grant vests 25% after one year from the Jan 28, 2026 vesting commencement date, then the remainder vests in 36 equal monthly installments.
  • F3: One grant vests 1/3 on each anniversary of Jan 28, 2026 (full vesting after three years).
  • F4: PSUs originally granted Jan 23, 2024 had performance metrics satisfied on Jan 28, 2026; those PSUs vest 2/3 on Mar 15, 2026 and 1/3 on Mar 15, 2027.
• No indication in the provided filing of tax-withholding share forfeiture or a 10b5-1 plan.

Context
These were compensation awards (restricted and performance RSUs), not open-market purchases or sales. RSUs/PSUs are contingent on time- and/or performance-based vesting; they represent the right to receive shares in the future if conditions are met. Such awards are common executive compensation and do not by themselves indicate a buy or sell signal in the market.